Clinical Trial

A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Business Decision
Summary
The goal of this clinical trial is to evaluate CLBR001 and SWI019 as a treatment for patients with autoimmune disorders, including systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myositis. Patients will be randomized 1:1 lymphodepletion vs no lymphodepletion arm. Patients will be administered a single infusion of CLBR001 cells followed by cycles of SWI019 with regular assessments of safety and disease response to treatment. The goals are to establish the safety and efficacy of the combination therapy and determine if lymphodepletion is required for efficacy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-03; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Withdrawn 2026-03-03
Trial Details
NCT Number NCT06913608
Lead Sponsor Calibr, a division of Scripps Research
Conditions Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Start Date 2026-03
Primary Completion 2026-03-03 (estimated)
Study Completion 2026-03-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-05